A Pilot Study of Intravenous EZN-2285 (SC-PEG E. Coli L-Asparaginase, IND 100594) or Intravenous Oncaspar in the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia.

Trial Profile

A Pilot Study of Intravenous EZN-2285 (SC-PEG E. Coli L-Asparaginase, IND 100594) or Intravenous Oncaspar in the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Calaspargase pegol (Primary) ; Pegaspargase
  • Indications Acute lymphoblastic leukaemia
  • Focus Pharmacokinetics; Registrational
  • Most Recent Events

    • 28 Feb 2017 According to a Leadiant Biosciences media release, this trial was originally conducted by Sigma-Tau Pharmaceuticals, Inc. but later on this company's name changed to Leadiant Biosciences
    • 06 Dec 2016 Results of preliminary analysis assessing anti-ASP (Pegaspargase) and anti-CASP (Calaspargase Pegol) antibodies, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 07 Jun 2016 Results (n=51) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top